Giapreza
Acute Kidney Injury
The Cleveland ClinicPhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Acute Kidney Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus MARIO ABBUD FILHO | Phase 4 | B |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Tanta University | Phase 4 | B |
Noradrenaline University of California, Los Angeles | Phase 4 | B |
NORMAL HUMAN SERUM ALBUMIN Institute of Liver and Biliary Sciences, India | Phase 3 | B |
PROPRANOLOL Taipei Veterans General Hospital, Taiwan | Phase 4 | B |
View all 32 →
Same molecule, other indications
Giapreza is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →